Total neoadjuvant treatment and pd-1/pd-l1 checkpoint inhibitor in locally advanced rectal cancer

HIGHLIGHTS

• who: Weiwei Xiao et al. from the Peter MacCallum Cancer Centre, Australia Southern Medical University, China have published the research: Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer, in the Journal: (JOURNAL)
• future: Studies are needed to investigate which patients are suitable for SCRT or LCRT. respectively (p=.26). While the value of TNT in low-risk LARC patients is also been praised even though evidence is still accumulating future studies are still important to gain more evidence on the possible benefits of TNT in low-risk patients . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.